However, it still remained challenging to design stapled PMI peptides that efficiently inhibit p53-dependent tumor growth in cell culture and, more importantly, in vivo, due in part to the rapid accumulation of both MDM2 and MDMX in cancer cells. The gene discussed is MDM4; the disease is cancer.